NoLEEta

Phase III non-inferiority trial of chemotherapy de-escalation in hormone receptor-positive, HER2-negative, intermediate-risk early breast cancer treated with Ribociclib (LEE- 011) in the adjuvant setting.

Coordinating Investigator

  • José Luis Sandoval

    José Luis Sandoval

    Médecin chef de clinique

The advent of CDK4/6 inhibitors (drugs designed to block the action of CDK4/6 proteins, which play a key role in cell proliferation) has improved treatment prospects for patients with metastatic breast cancer whose tumour cells express hormone receptors but not the HER2 protein (HR+/HER2-). The NATALEE study showed that the addition of ribociclib for three years to conventional adjuvant hormone therapy (i.e. after surgery) prolonged survival free of invasive disease (i.e. extending to surrounding tissues) in patients with early HR breast cancer+ /HER2-. Unlike other studies, NATALEE included a group of patients at intermediate risk of recurrence, usually treated with adjuvant chemotherapy before receiving hormone therapy. However, the benefit of adjuvant chemotherapy in these patients is uncertain. The hypothesis of the NoLEEta study is that by using the CDK 4/6 inhibitor, patients could avoid adjuvant chemotherapy and therefore be spared the side- effects associated with this chemotherapy, without reducing the efficacy of the treatment.

Objectives 

The primary objective of NoLEEta is to demonstrate that the combination of ribociclib with hormone therapy is as effective as the same treatment preceded by adjuvant chemotherapy in patients with non-metastatic breast cancer.The secondary objectives are to evaluate the efficacy, safety and tolerability of the treatments and quality of life in the 2 groups of patients.

Primary endpoint of the trial 

The primary endpoint of the trial is invasive breast cancer-free survival (iBCFS) (i.e. the average length of time patients live with their disease without signs of cancer recurrence).

Secondary endpoints of the trial 

The efficacy of the treatment will also be assessed by the average length of time patients live with the disease without signs of spread to neighbouring tissues or other organs, and the time interval between the start of treatment and death, if this occurs during the study. The study will also assess patients' tolerance of treatment and quality of life.

Trial design 

A phase III multicentre, randomised (patients are randomly assigned to the treatment arm) chemotherapy de-escalation trial designed to show that the addition of ribociclib for 3 years to hormonal treatment is as effective as the same treatment preceded by adjuvant chemotherapy in patients with non-metastatic breast cancer at intermediate risk of recurrence who have undergone surgery. Eligible patients will be enrolled in the experimental arm, where they will receive a combination of ribociclib and hormonal treatment, or in the control arm, where they will receive chemotherapy first, followed by a combination of ribociclib and hormonal treatment. Patients will remain in the trial for no more than 8.5 years after randomization.

Trial population

Adult patients (≥18 years) with invasive breast cancer at intermediate risk of recurrence. They must have undergone curative surgery, be able to receive chemotherapy, be in good general health with normal haematological, renal and hepatic function. They must not have received prior treatment with a CDK4/6 inhibitor or chemotherapy, have no active autoimmune disease or other serious uncontrolled diseases, and have no history of invasive cancer within 2 years prior to inclusion.

Interventions 

After signing the consent form, patients will enter the pre-inclusion period (up to 28 days before the start of treatment), during which the investigator will carry out all the necessary tests to assess their eligibility. If patients are eligible, they will be randomly assigned to treatment: 

  • The experimental group will receive the ribociclib combination for 3 years and hormonal treatment for at least 5 years (consisting of aromatase inhibitors and, for pre-menopausal women, GnRH agonists). 
  • The control group will receive the same treatment with approximately 6 months of chemotherapy beforehand. 

To receive the treatment, patients will have to go to hospital where, at each visit, the medical team will carry out medical examinations before administering the treatment, in order to assess the patient's general state of health and tolerance of the treatment. After stopping ribociclib treatment, patients will be followed up in hospital every 6 months until the end of the first 5 years of hormone therapy, and then once a year until the end of the trial.

Hospitals

  • Centre du sein Fribourg - Brustzentrum Freiburg
    Centre du sein Fribourg - Brustzentrum Freiburg
  • Clinique Générale-Beaulieu
    Clinique Générale-Beaulieu
  • Kantonsspital Aarau AG
    Kantonsspital Aarau AG
  • Kantonsspital Baselland
    Kantonsspital Baselland
  • Kantonsspital Winterthur
    Kantonsspital Winterthur
  • Les hôpitaux universitaires de Genève
    Les hôpitaux universitaires de Genève
  • Onkologie Bellevue
    Onkologie Bellevue
  • St. Claraspital AG
    St. Claraspital AG

Further Studies: Breast cancer

SAKK 66/22

Triple-negative (hormone-independent) breast cancer, TNBC

Recruitment completed

SAKK 23/16 TAXIS

Surgical lymph node removal with the option of “extensive operation” or “radiotherapy” in breast cancer patients with existing axillary lymph node involvement

Recruitment completed

CAMBRIA-2

Researchers are looking for a better way to treat ER+/HER2- early-stage breast cancer

SAKK 23/18 - VISION I

Breast cancer: is surgery still necessary if tumor tissue can no longer be detected following chemotherapy?

SAKK 21/23 NEODOXy

Does doxycycline improve breast cancer treatment?

Recruitment completed

IBCSG 50-14 OLYMPIA

A randomised, double-blind, parallel group, placebo-controlled multi-centre Phase III study to assess the efficacy and safety of olaparib versus placebo as adjuvant treatment in patients with germline BRCA1/2mutations and high risk HER2 negative primary breast cancer who have completed definitive local treatment and neoadjuvant or adjuvant chemotherapy.

Recruitment completed

IBCSG 52-15 PALLAS

PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer.

Recruitment completed

IBCSG 67-22 PREcoopERA

A Window-of-Opportunity trial of giredestrant +/- triptorelin vs. anastrozole + triptorelin in premenopausal patients with ER-positive/HER2-negative early breast cancer.

Recruitment completed

IBCSG 48-14 POSITIVE

A study evaluating the pregnancy outcomes and safety of interrupting endocrine therapy for young women with endocrine responsive breast cancer who desire pregnancy (POSITIVE).

OPBC-10/ NOAX

International study comparing radiotherapy and complete surgical removal of the axillary lymph nodes in patients with breast cancer and affected lymph nodes